Evidence shows that hypertension and diabetic patients, who therapeutically receive ACE inhibitors (ACEIs) and AT1R blockers (ARBs), have elevated ACE2 levels and could be at high-risk for COVID-19 infection. Here, ACE2 is linked to hypertensive disorder.